|
|
|
|
|
|
|
|
|
27.10.25 - 11:03
|
Revvity Announces Financial Results for the Third Quarter of 2025 (Business Wire)
|
|
|
Revenue of $699 million; 2% reported growth; 1% organic growth
GAAP EPS of $0.40; Adjusted EPS from continuing operations of $1.18
Reaffirms full year 2025 organic growth and raises adjusted EPS guidance
Authorizes new $1 billion share repurchase program
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.
The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP operating profit margin from continuing operations was 11.7% as a percentage of revenue, as compared to 14.3% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $1.28 in the same period a year...
|
|
|
|
|
23.10.25 - 22:09
|
Revvity Board Declares Quarterly Dividend (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.
About Revvity
At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has cu...
|
|
|
|
|
|
|
|
|
15.10.25 - 23:51
|
XFRA: DIVIDEND/INTEREST INFORMATION - 17.10.2025 - US7140461093 (XETRA)
|
|
|
Das Instrument PKN US7140461093 REVVITY INC. DL 1 EQUITY wird cum Dividende/Zinsen gehandelt am 16.10.2025 und ex Dividende/Zinsen am 17.10.2025
The instrument PKN US7140461093 REVVITY INC. DL 1 EQUITY has its pre-dividend/interest day on 16.10.2025 and its ex-dividend/interest day on 17.10.2025...
|
|
|
|
|
06.10.25 - 14:03
|
Revvity to Hold Earnings Call on Monday, October 27, 2025 (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
To access the call, a live audio webcast will be available on the Investors section of the Company's website.
About Revvity
At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
